Prenatal activation of toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring by Forrest, C.M. et al.
  
 
 
 
 
Forrest, C.M., Khalil, O.S., Pisar, M., Smith, R.A., Darlington, L., and 
Stone, T.W. (2012) Prenatal activation of toll-like receptors-3 by 
administration of the viral mimetic poly(I:C) changes synaptic proteins, N-
methyl-D-aspartate receptors and neurogenesis markers in offspring. 
Molecular Brain, 5 (22). ISSN 1756-6606 
 
 
Copyright © 2012 The Authors 
 
 
 
http://eprints.gla.ac.uk/75320/ 
 
 
 
 
Deposited on: 14  February 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Forrest et al. Molecular Brain 2012, 5:22
http://www.molecularbrain.com/content/5/1/22RESEARCH Open AccessPrenatal activation of Toll-like receptors-3 by
administration of the viral mimetic poly(I:C)
changes synaptic proteins, N-methyl-D-aspartate
receptors and neurogenesis markers in offspring
Caroline M Forrest1, Omari S Khalil1, Mazura Pisar1, Robert A Smith1, Lynda Gail Darlington2 and Trevor W Stone1*Abstract
Background: There is mounting evidence for a neurodevelopmental basis for disorders such as autism and
schizophrenia, in which prenatal or early postnatal events may influence brain development and predispose the
young to develop these and related disorders. We have now investigated the effect of a prenatal immune
challenge on brain development in the offspring. Pregnant rats were treated with the double-stranded RNA
polyinosinic:polycytidylic acid (poly(I:C); 10 mg/kg) which mimics immune activation occurring after activation of
Toll-like receptors-3 (TLR3) by viral infection. Injections were made in late gestation (embryonic days E14, E16 and
E18), after which parturition proceeded naturally and the young were allowed to develop up to the time of
weaning at postnatal day 21 (P21). The brains of these animals were then removed to assess the expression of 13
different neurodevelopmental molecules by immunoblotting.
Results: Measurement of cytokine levels in the maternal blood 5 hours after an injection of poly(I:C) showed
significantly increased levels of monocyte chemoattractant protein-1 (MCP-1), confirming immune activation. In the
P21 offspring, significant changes were detected in the expression of GluN1 subunits of NMDA receptors, with no
difference in GluN2A or GluN2B subunits or the postsynaptic density protein PSD-95 and no change in the levels of
the related small GTPases RhoA or RhoB, or the NMDA receptor modulator EphA4. Among presynaptic molecules, a
significant increase in Vesicle Associated Membrane Protein-1 (VAMP-1; synaptobrevin) was seen, with no change in
synaptophysin or synaptotagmin. Proliferating Cell Nuclear Antigen (PCNA), as well as the neurogenesis marker
doublecortin were unchanged, although Sox-2 levels were increased, suggesting possible changes in the rate of
new cell differentiation.
Conclusions: The results reveal the induction by prenatal poly(I:C) of selective molecular changes in the brains of
P21 offspring, affecting primarily molecules associated with neuronal development and synaptic transmission. These
changes may contribute to the behavioural abnormalities that have been reported in adult animals after exposure
to poly(I:C) and which resemble symptoms seen in schizophrenia and related disorders.
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A substantial amount of clinical epidemiological evidence
has suggested that human maternal infection during preg-
nancy can adversely affect brain development of the off-
spring in postnatal life [1,2]. Maternal infection could,
therefore, represent an important contributor to the emer-
gence of neurodevelopmental disorders including schizo-
phrenia, autism spectrum disorders and depression [3-5].
This hypothesis is supported by experimental evidence
from rodent models that infection during gestation may
lead to behavioural changes in the offspring which may
not be apparent until adulthood. Those behavioural ab-
normalities often resemble features of the neurodevelop-
mental disorders seen in humans [6-8]. In order to
prevent or treat neurodevelopmental disorders of this kind
it will be essential to understand the molecular changes by
which infection of the mother, foetus or neonate influ-
ences brain development and its subsequent maturation.
Animal models for the effects of infection on develop-
ment have been described [9,10]. Many infections of
pregnancy are caused by viruses, the effects of which
can be simulated by the synthetic viral coat-mimetic
poly-[inosinic acid:cytidylic acid], (poly(I:C)). This
double-stranded RNA molecule activates Toll-Like Re-
ceptor-3 (TLR-3) on dendritic cells, macrophages and B
cells, leading to activation of the immune system. The
effects of poly(I:C) include inducing the expression of
interferon-γ (IFN-γ) and other major inflammatory med-
iators such as interleukin-1β (IL-1β), IL-6 and tumour
necrosis factor-α (TNF-α), as well as leucocyte chemoat-
tractants such as monocyte chemotactic protein-1
(MCP-1) [11], thus reproducing many features of a full
infective immune response.
In the present study pregnant female rats were treated
with poly(I:C) during the late phases of gestation. Partur-
ition was then allowed to proceed normally and the off-
spring were allowed to grow until weaning (postnatal
day 21; P21) when the expression of molecules known to
play critical roles in early brain development or which
reflect the formation of synaptic contacts were studied.
The results indicate that several of these molecules show
substantial changes which persist at least until the time
of weaning and which may underlie aspects of the be-
havioural abnormalities reported previously.
Methods
Animals
This study was carried out according to the regulations of
the Animals (Scientific Procedures) act 1986 of the UK,
administered and monitored by the Home Office. The
study was performed according to internationally recog-
nized procedures and was approved by the University of
Glasgow Research Ethics Committee. Male and female
Wistar rats were housed together for mating andinspected daily for the occurrence of a vaginal plug. The
pregnant females were housed alone from that point, with
free access to food and water. Preliminary experiments
established that 10 mg/kg of poly(I:C) could be given to
pregnant dams during the last seven days of gestation with
no signs of stress, behavioural changes or abnormal be-
haviour towards the neonatal pups after birth.
A dose of 10 mg/kg was used partly based on the exist-
ing literature reporting that doses of 5 or 10 mg/kg are
able to induce a clear inflammatory response in rodents
[12] whereas lower doses are generally ineffective. How-
ever, much of this previous work was performed in normal
adult or neonatal animals, and involved single injections
whereas we wished to develop a model in which the im-
mune system was activated over a time period of several
days. We therefore performed preliminary experiments
using different doses and injection schedules of poly(I:C)
specifically in pregnant rats during late gestation. The
results supported the adult data, firstly confirming that
10 mg/kg could be used without evoking any sickness be-
haviour (hyperpyrexia, lethargy, hyper-sensitivity, anor-
exia) after a single injection and showing that the same
dose could be administered on three separate occasions
with a similar lack of adverse effects on the pregnant dam.
This provides confidence that our dose is well-tolerated,
and it was therefore selected to give the maximum chance
of seeing changes in the offspring. The acceptability of this
dose was confirmed by the fact that litter sizes were not
affected, with an average litter size of 10.4 in saline-treated
dams compared with 10.33 in animals receiving poly(I:C),
confirming that the 10 mg/kg dose was having no adverse
effects on mother or litter in utero or on the progress of
gestation.
Poly(I:C; P0913) was obtained from Sigma (Poole, UK)
and was prepared for injection by dissolving 10 mg in
1 ml of sterile saline (0.9%w/v NaCl). It was heated to 50°C
to ensure complete solubility and allowed to cool to
room temperature to allow re-annealing of the double-
stranded RNA. Pregnant rats were injected intraperitone-
ally with 10 mg/kg poly(I:C) or vehicle (sterile saline 0.9%)
on gestation days E14, E16 and E18 in order to extend the
temporal impact of maternal immune activation on the
embryos, with no apparent ill effects on the dam or her
behaviour towards her litter after birth. All injections were
administered between 9 am and 11 am to minimise vari-
ation in responses. Following the injections, gestation was
allowed to proceed normally, with neonates being allowed
to survive until weaning (postnatal day 21; P21) when they
were taken from the home cage for euthanasia followed
by removal of the brain. Each brain was divided into the
two cerebral hemispheres and frozen immediately on dry
ice before being transferred to storage at −80°C until
required for analysis. Each member of a litter was treated
identically, with whole litters being taken at the same time
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losing littermates while themselves surviving to a later
date. This protocol also ensured that changes of maternal
behaviour caused by the removal of some pups could not
affect the development of survivors.
Cytokine analysis
For assessment of cytokine production following poly(I:C)
challenge, pregnant females were administered a single
injection of either poly(I:C) 10 mg/kg or vehicle (sterile
saline 0.9%) on gestational day E18. Rats were sacrificed
5 h later and blood was collected by cardiac puncture
using sterile syringes into sterile tubes containing 20U/ml
heparin. The samples were then centrifuged at 600 g for
15 minutes, and maternal plasma was stored at −80°C
until required for cytokine analysis.
The levels of the pro-inflammatory cytokines interleu-
kin-1β (IL-1β) and tumour necrosis factor-α (TNF-α),
and the chemokine monocyte chemoattractant protein-1
(MCP-1) were analysed using Signosis ELISA profiling
kits (Caltag Medsystems, Buckingham, UK). The relative
amounts of these proteins present in the maternal
plasma of pregnant animals treated with vehicle or poly
(I:C) were calculated from the optical densities read at
450 nm using a microplate reader.
Immunoblotting
Brain sample homogenates were prepared in RIPA buffer
(50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% Triton X-
100, 1% IGEPAL, and a Roche complete protease inhibitor
tablet) and centrifuged at 18000 g for 5 min at 4°C. Super-
natants were collected for protein concentration deter-
mination using the Bio-Rad Coomassie Blue protein assay
(Bio-Rad, Hemel Hempstead, UK). Samples were then
normalised to 10 μg and prepared as; 65% protein sample,
25% sample buffer and 10% reducing agent (Life Tech-
nologies, Paisley, UK), and heated at 70°C for 10 min. The
protein samples were loaded onto NuPAGE Novex 4–12%
Bis-Tris (1.0 mm) 15 lane gels (Life Technologies, Paisley,
UK) and run at 150 volts for 80 min to separate proteins
according to their molecular weight. SeeBlue pre-stained
standard (Life Technologies, Paisley, UK) was included on
each gel as a molecular weight marker. The separated pro-
teins were then blotted onto Invitrolon poly(vinylidene
difluoride) membranes (Life Technologies, Paisley, UK) at
30 V for 60 min. The membranes were blocked for 1 h in
5% non-fat dried milk solution in Tris-buffered saline con-
taining 0.05% Tween (TBST), before overnight incubation
at 4°C with the appropriate primary antibody (diluted in
5% milk-TBST). Membranes were then washed 3 times
for 15 min with TBST and incubated with the appropriate
horseradish peroxidase (HRP) conjugated secondary anti-
body (prepared in 5% milk-TBST) for 1 h at room
temperature. Following secondary antibody incubation,blots were washed 3 times for 15 min with TBST then
visualised using Enhanced Chemiluminescence Plus detec-
tion kit (GE Healthcare, Chalfont St Giles, UK).
Antibodies
Western blot analysis was carried out using the following
primary antibodies raised against target proteins: GluN1
(mouse monoclonal, 05–432, 1 : 1000 dilution) and synap-
tophysin (mouse monoclonal, MAB368, 1 : 40000 dilu-
tion) (Millipore, Watford, UK); GluN2A (rabbit
polyclonal, PPS012, 1 : 5000 dilution), GluN2B (rabbit
polyclonal, PPS013, 1 : 5000 dilution), VAMP-1/synapto-
brevin (goat polyclonal, AF4828, 1 : 10000 dilution), and
synaptotagmin (mouse monoclonal, MAB43641, 1 : 5000
dilution) (R&D Systems, Abingdon, UK); PSD-95 (rabbit
monoclonal, 3450, 1 : 10000 dilution) (Cell Signalling,
New England Biolabs, Hitchin, UK); RhoA (mouse mono-
clonal, sc-418, 1 : 1000 dilution), RhoB (mouse monoclo-
nal, sc-8048, 1 : 1000 dilution), EphA4 (rabbit polyclonal,
sc-921, 1 : 5000 dilution), PCNA (mouse monoclonal, sc-
56, 1 : 1000 dilution), doublecortin (goat polyclonal, sc-
8066, 1 : 1000 dilution), Sox-2 (goat polyclonal, sc-17320,
1 : 500 dilution) and actin (goat polyclonal, sc-1615, 1 :
10000 dilution) (Santa Cruz, Insight Biotechnology, Wem-
bley, UK). The following secondary HRP-conjugated anti-
bodies were used at 1: 5000 dilution: goat anti-rabbit HRP
(12–348) (Millipore, Watford, UK); donkey anti-goat HRP
(sc-2020) and goat anti-mouse (sc-2005) (Santa Cruz,
Insight Biotechnology, Wembley, UK).
Data analysis and statistics
The western blots were analysed using Image J densitomet-
ric software (http://rsb.info.nih.gov/ij/). In order to control
for variations in the total amount of protein loaded onto
gels, all membranes were stained with Ponceau S solution
(Sigma, Poole, UK). In addition, actin expression was
examined in each series of blots and all results are
expressed as the ratio of the intensity of target protein rela-
tive to actin intensity. Three pregnant rats were injected in
each of the treatment groups and two pups from each litter
were randomly selected for western blot analysis. Statistical
comparisons were made, using Instat software, between
groups of pups born to mothers treated with poly(I:C)
(n= 5–6) and groups born to mothers injected with saline
vehicle (n=5–6). This protocol allowed the use of an un-
paired t-test to examine differences between the two. A
probability value of approximately 0.05 was adopted as the
working criterion for significance, but precise p-values are
indicated when >0.0001.
Results
Cytokine levels
The time point chosen for confirmation of a systemic in-
flammatory response to poly(I:C) – 5 hours following
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in one of the most important and well-recognised che-
mokines, monocyte chemoattractant protein-1 (MCP-1).
The levels of this compound in the maternal blood is
summarised in Figure 1, which indicates a significant in-
crease in concentration, confirming the efficacy of the
poly(I:C) dose used here. At this 5 h time point, no
changes were noted in the levels of interleukin-1β (IL-1β)
or TNF-α. This is consistent with previous work showing
that an increase in TNF-α reaches a peak around 2-3 h
following poly(I:C) administration in vivo [12,13], while
others have reported no change in IL-1β levels after
injection of poly(I:C) [14,15].
The fact that levels of IL-1β and TNF-α were not
increased does confirm that the animals used in this
study were not experiencing any ongoing, baseline in-
flammatory activity – if there were any endogenous in-
fection or inflammatory condition such as arthritis,
there would be a chronic and maintained increase of
these cytokines that would be detectable before and after
the injection of poly(I:C). On the other hand, it should
be emphasised that these comments apply to maternal
blood since brains from the embryos were not examined
in this study and we cannot exclude the possibility that
changes occurred in the foetal brain that are not mir-
rored in the maternal circulation.Neuronal proteins
The expression of selected target molecules was exam-
ined using Western blotting. The molecules examined
are major components of the synaptic vesicle ando
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Figure 1 Maternal levels of MCP-1. Bar chart showing the
maternal blood levels of monocyte chemoattractant protein-1
(MCP-1) measured 5 h following the administration of poly(I:C)
10 mg/kg. Values are shown as the mean ± s.e.mean (n = 3) in
arbitrary units of optical density (OD).neurotransmitter release machinery such as synaptophy-
sin and Vesicle Associated Membrane Protein-1
(VAMP-1; synaptobrevin) as well as the vesicular release
calcium sensor synaptotagmin. In addition, since N-me-
thyl-D-aspartate (NMDA) receptors are known to play
important roles in neurite outgrowth and guidance as
well as synapse formation, the GluN1 subunit was exam-
ined, together with the Post-Synaptic Density molecule-
95 (PSD-95), a major component of the post-synaptic
complex that includes and modulates NMDA receptor
function. We have also sought changes in the two major
small GTPases, RhoA and RhoB, both of which have
been implicated in the regulation of cytoskeletal proteins
and which have been shown to be involved in synaptic
transmission and plasticity [16,17].
In the brains from P21 pups exposed to poly(I:C), the
expression of neither synaptophysin (p= 0.54; Figure 2A)
nor synaptotagmin (p= 0.56; Figure 2B) showed any sig-
nificant difference from control pups from saline-treated
dams. VAMP-1, however, showed a significant increase
compared with controls (p= 0.027; Figure 2C).
Two of the small RhoGTPase enzymes were also
examined but there was no significant difference in the
expression of either RhoA (p= 0.91, Figure 3A) or RhoB
(p= 0.78, Figure 3B) between poly(I:C)-treated and con-
trol animals.
The greatest change noted in these animals was of the
GluN1 subunit of NMDA receptors, which showed a
highly significant decrease compared with pups from ve-
hicle-treated dams (p= 0.01; Figure 4A). In contrast, ex-
pression of the GluN2A (p= 0.12; Figure 4B) and
GluN2B (p= 0.64; Figure 4C) subunits were not altered
in pups exposed to poly(I:C). Similarly, expression of the
post-synaptic density marker PSD-95 showed no change
between controls and treated pups (p= 0.51; Figure 4D).
In addition to the above molecules, which have clearly
documented roles in the early formation of synaptic con-
tacts and in functional synaptic transmission, we have
examined several molecules with more generic roles in
neuronal proliferation of maturation. Proliferating Cell
Nuclear Antigen (PCNA) is widely used as a marker of
neurogenesis but its expression was not altered signifi-
cantly following poly(I:C) (p= 0.64; Figure 5A). The
levels of doublecortin, an intracellular protein required
for neuronal migration during prenatal and early post-
natal development, was not affected by poly(I:C) treat-
ment (p= 0.95; Figure 5B).
Also within this group of markers is the sox-2 protein
which has been implicated in neurogenesis in the brain
[18] and cells deficient in sox-2 exhibit reduced neuro-
genesis [19]. Following exposure to poly(I:C) in utero,
the expression of Sox-2 was significantly increased in
the P21 pups compared with control neonates (p= 0.01,
Figure 5C).
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Figure 2 Expression of synaptic proteins. Bar charts showing the quantified expression of (A) synaptophysin (M.W.40 kDa) (B) synaptotagmin
(M.W. 57 kDa) and (C) Vesicle Associated Membrane Protein-1 (VAMP-1; synaptobrevin; M.W. 14 kDa) in the brains of P21 rat offspring after
treating the mothers with poly(I:C) 10 mg/kg on days E14, E16 and E18 of gestation. The bars indicate the mean ± s.e.mean (n = 5–6) in arbitrary
units of optical density (OD) expressed as the ratio of test protein to actin. Sample western blots above each chart illustrate the data obtained
from animals exposed to the saline vehicle (S) or poly(I:C) (P) and show the relevant protein and the corresponding actin blot used as a
housekeeping marker * P< 0.05.
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members of the ephrin ligands and their Eph receptors
are associated with axogenesis, synapse formation and
function. In pups exposed to poly(I:C) expression of
EphA4 was unchanged relative to saline-treated pups
(p= 0.12; Figure 5D).
Discussion
The generation of a maternal immune or inflammatory
response during pregnancy leads to a range of changes
in the brains of the offspring which have strong parallels
with those found in human behavioural disorders such
as autism and schizophrenia. The administration of ei-
ther bacterial lipopolysaccharides or the viral mimetic
poly(I:C), (compounds frequently used in models of pre-
natal infection) can induce electrophysiologicalalterations in synaptic transmission [20-22] and elements
of cognitive function [21,23,24] as well as changes in the
levels of some major neurotransmitters [25]. Here we
have used poly(I:C) to activate an immune response via
TLR-3 in the late stages of gestation, a time when sus-
ceptibility of the rat foetal brain is believed to be com-
parable with that of the human brain in the second
trimester of pregnancy, since brain development is at a
comparable stage [26].
The measurement of cytokine and chemokine levels
here confirms the ability of poly(I:C) to activate the in-
nate immune system since the expression of MCP-1 is
increased 5 h after its injection. The lack of any change
in IL-1β or TNF-α levels confirms the absence of any
on-going, background immune system activity, as in vivo
administration of poly(I:C) is known to induce a rapid
AB
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Figure 3 Expression of Rho proteins. Bar charts showing the
quantified expression of (A) RhoA (M.W. 24 kDa) and (B) RhoB
(M.W. 25 kDa) in the brains of P21 rat offspring after treating the
mothers with poly(I:C) 10 mg/kg on days E14, E16 and E18 of
gestation. The bars indicate the mean ± s.e.mean (n = 5–6) in
arbitrary units of optical density (OD) expressed as the ratio of test
protein to actin. Sample western blots above each chart illustrate
the data obtained from animals exposed to the saline vehicle (S) or
poly(I:C) (P) and show the relevant protein and the corresponding
actin blot used as a housekeeping marker.
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2–3 h post-injection, with levels reportedly returned to
control values by 4–6 h [13-15]. In addition, Gilmore
and co-workers [12] have previously shown that admin-
istration of Poly(I:C) to pregnant rats at E16 significantly
elevated TNF-α in the maternal plasma at 2 h post-injection, with no increase detectable by 8 h. Poly(I:C)
administered to mice at 12 mg/kg has previously been
reported to induce plasma IL-1β 3 h post-treatment
[13], whereas, in agreement with our finding, other
groups have failed to detect increases in this cytokine
after poly(I:C) administration in vivo [14,15]. Examin-
ation of mRNA for cytokines after treatment with poly
(I:C) also suggests a transient profile, with peak up-regula-
tion of genes occurring 3-6 h after poly(I:C), with only a
few genes remaining elevated 24 h post-injection [27].
On the other hand, it should be emphasised that these
comments apply to maternal blood since brains from
the embryos were not examined in this study. Thus, we
cannot exclude the possibility that changes occurred in
the foetal brain that are not mirrored in the maternal
circulation, although we are not aware of any previous
evidence for this. However, we can exclude the initiation
of an inflammatory response that persists from the ad-
ministration of poly(I:C) through to the P21 stage when
the offspring were examined. This is based partly on
published data showing that the elevation of cytokines
does not persist much beyond 24hours after injection. In
addition, we have noted that there is no change of in-
flammatory markers such as cyclo-oxygenase-2 or NFkB
at P21 as would be the case if there existed a continuing
activation of the immune system (Pisar, Forrest, Omari,
Darlington and Stone, unpublished observations).
It is clear from the present study that a number of sig-
nificant changes are induced by the inflammatory chal-
lenge. The synaptic vesicle proteins synaptophysin,
synaptotagmin and VAMP-1 (synaptobrevin), are of par-
ticular interest in brain development, and VAMP-1 has
been noted as one of 18 proteins whose gene increases
continually from postnatal day P0 to P45. Clear changes
in several synaptic vesicle release proteins have been
demonstrated in brain tissue from schizophrenic patients
[28-30] where the most marked changes are in the levels
of synaptophysin and VAMP-1 [29]. Treatment of preg-
nant dams in the present study did not produce any sig-
nificant change in the expression of synaptophysin or
the synaptic vesicle calcium sensor protein synaptotag-
min. This result is consistent with a study by Afadlal
et al. [31] in which prenatal stress induced by maternal
restraint or corticosterone injections produced a de-
crease in synaptophysin levels only in animals at P7 or
P14, but not at later ages such as the P21, post-weaning
time examined here. On the other hand the levels of
VAMP-1 were affected to a significant degree, emphasising
the potential parallels between the effects of poly(I:C) and
the changes reported in schizophrenia [29].
An increasingly recognized view of the molecular
changes underlying schizophrenia postulates a hypofunc-
tion of NMDA receptors. It is already established that
neuronal receptors for glutamate, especially those
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Figure 4 Expression of NMDA receptor-associated proteins. Bar charts showing the quantified expression of (A) GluN1 (M.W. 130 kDa) (B)
GluN2A (M.W. 180 kDa) (C) GluN2B (M.W. 180 kDa) and (D) PSD-95 (M.W. 95 kDa) in the brains of P21 rat offspring after treating the mothers with
poly(I:C) 10 mg/kg on days E14, E16 and E18 of gestation. The bars indicate the mean ± s.e.mean (n = 6, except GluN1 poly(I:C) where n = 5) in
arbitrary units of optical density (OD) expressed as the ratio of test protein to actin. Sample western blots above each chart illustrate the data
obtained from animals exposed to the saline vehicle (S) or poly(I:C) (P) and show the relevant protein and the corresponding actin blot used as a
housekeeping marker ** P< 0.01.
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apse formation [33], and neurite growth [34], spine for-
mation [35,36] and neuronal plasticity [6,37,38]. The
pharmacological blockade of NMDARs in neonatal rats
causes a loss and disruption of synapses with profound
abnormalities of brain structure and behaviour in adult-
hood [39-41], many of which resemble the behavioural
abnormalities which occur in schizophrenia [42]. Thus,
an induced change in NMDA receptor function during
development could modify (for example by accelerating
or slowing, amplifying or suppressing) the normal pro-
cesses of programmed neuronal elimination which
shapes the early nervous system.
In light of this fundamental role of NMDAR in neuron
and synapse formation and function, the present finding
of substantially reduced expression of the major subunitof these receptors could imply that a change in NMDAR
number or function could underlie some of the neuro-
chemical and behavioural abnormalities which have been
described after exposure of animals to LPS or poly(I:C)
[21,23,24]. NMDARs are composed of GluN1 and
GluN2 subunits which bind glutamate and exert a regu-
latory control over GluN1. The GluN1 subunit is
encoded by one gene to produce several splice variants.
The antibody used in this work was selected as it inter-
acts with all of the known splice variants. The change in
GluN1 expression, therefore, reflects a real overall
change of NMDAR number or function. Changes similar
to those observed here have been reported previously in
the expression of GluN1 receptors, although the experi-
mental design was substantially different, with LPS injec-
tions or viral infection being induced directly in the
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during gestation [40,43]. Nevertheless, taken together,
these various studies offer highly suggestive mutual sup-
port for the concept that activation of the immune sys-
tem can interfere with NMDAR function during brain
development.
The small GTPases RhoA and RhoB have repeatedly
been linked with synaptic plasticity [16,17,44] and vari-
ous aspects of neuronal development [45,46], often me-
diating the effects of NMDAR. However, there were no
clearly significant changes in their expression. Similarly,
despite the role of the tyrosine kinase family of Eph
receptors and their ephrin ligands in synaptogenesis [47]
and spine formation [48-50] the absence of any clear
change in the level of EphA4 implies that it does not
contribute to changes in neuronal development and be-
haviour produced by poly(I:C).
There was a significant increase in the expression of
Sox-2 (sex-determining region Y-related HMG-box2), atranscription factor involved in stem cell maintenance in
the brain as well as a major factor in regulating cell loss
or survival during development [51]. Sox-2 is often con-
sidered a marker of cells that are actively dividing but
which are in the early phases of proliferation and are as
yet undifferentiated [52]. Sox-2 occurs primarily in brain
regions that contain actively proliferating neural stem
cells, possibly maintaining a ‘latent’ and undifferentiated
state [53,54]. Suppression or deletion of sox-2 can lead
to increased apoptosis [19] and is incompatible with em-
bryonic survival [55], although overexpression does not
promote proliferation [56]. The pattern of changes seen
in this group of neurogenesis markers, therefore, sug-
gests a possible increase in the number of cells (as yet
undifferentiated) at an early stage of proliferation. How-
ever, since no change was detected in the expression of
PCNA, a nuclear protein which is increasingly used as a
marker for the early phases of cell degeneration [51], the
sox-2 expressing cells either do not express this protein
Forrest et al. Molecular Brain 2012, 5:22 Page 9 of 12
http://www.molecularbrain.com/content/5/1/22at P21, or they have past the stage of producing PCNA.
Similarly there was no change in levels of doublecortin,
a molecule associated primarily with later stages of
neurogenesis and whose expression declines during
brain development. This observation suggests that poly
(I:C) administration does not produce significant overall
changes in neuronal or glial generation at P21.
A major question which arises following the induction
of inflammation by poly(I:C) or bacterial polysaccharides
(LPS) is whether any observed effects are a direct action
of the injected agent, or are secondary, indirect conse-
quences mediated via an intermediate compound. It is
improbable that the immunostimulator molecules are
themselves responsible, since they are unlikely to cross
into embryos. In one study, radiolabelled LPS was admi-
nistered to pregnant dams but the labelled compound
was detected only in maternal tissues and not in the
embryos [57].
The compounds that have been most often considered
in the role of mediating immunostimulant effects in the
brain are the cytokines. It is well recognised that both
poly(I:C) and LPS can induce the expression and release
of several pro-inflammatory cytokines although they can
also modify the expression of neurotrophic proteins such
as brain-derived growth factor (BDNF) and nerve
growth factor (NGF), all of which have profound effects
themselves on the CNS.
The administration of poly(I:C) does increase plasma
levels of IL-1β, IL-6, TNF-α and interferon-β in adult
rats when measured at the appropriate time points
[12,13] and both IL-1β and TNF-α have been detected
within the brain after systemic administration of LPS or
poly(I:C) [58-60]. This expression of cytokines has also
been shown after maternal administration of LPS, when
expression of IL-1β, IL-6 and TNF-α, as well as MCP-1
was demonstrated within the brains of the embryos [61].
These results seem to depend acutely on the precise ex-
perimental protocol since others have found that the ex-
pression of TNF-α was reduced by LPS in the foetal
brain, whereas poly(I:C) had no effect [12]. Other work-
ers have reported finding either no change of foetal
brain TNF-α [62] or an increase [63].
Some of the most compelling work is that which
shows the ability of cytokine antagonists to prevent CNS
features of inflammation such as microglial activation,
neuronal death or cognitive dysfunction. Some of these
effects can be prevented by an IL-1β receptor antagonist
[58,64], although the direct administration of IL-1β to
pregnant dams has been reported not to result in
changes in the offspring.
Certainly, both neurons and glial cells possess interleu-
kin receptors and there have been many studies showing
that a range of cytokines, including IL-1β, have marked
effects in the CNS even after peripheral delivery [65].Work by Riazi et al., [59,60] has shown that poly(I:C)
can increase the CNS levels of IL-1β, the cytokine which
was probably responsible for the observed increase in
CNS excitability and susceptibility to seizures induced
by pilocarpine or pentylenetetrazol. Interestingly these
effects were accompanied by an increased expression of
GluN2A and GluN2C subunits which did not occur in
the present study, presumably because of the difference
between direct administration into the postnatal brain
rather than administration into the mother followed by
examination of the offspring.
Although most attention on cytokine mediation of
poly(I:C) effects has been concentrated on IL-1β, there
are several alternative candidates, such as IL-6. When la-
belled IL-6 was injected into pregnant rats, the protein
was found in the amniotic fluid and in the foetus itself
[66] showing its ability to pass across the placental bar-
rier. In addition, maternal IL-6 administration has been
reported to reproduce many of the effects of poly(I:C)
on offspring, a claim strongly supported by the finding
that antagonism of IL-6 prevented the effects of poly(I:C)
[9,10].
The problem of identifying a likely mediator of poly(I:C)
effects is complicated further by the fact that neurons and
glia can express several cytokines including IL-1β and
TNF-α [67], so that the passage of cytokines into the CNS
may not even be required for them to mediate genetic
changes within the brain. It may only be necessary that
neurons or glia are activated by a small molecule factor
which can pass readily between blood and brain. However,
Oskvig et al. [68] have noted that cytokine protein levels
are increased within the foetal brain whereas the corre-
sponding RNA molecules are not, implying that the foetal
proteins are derived from the maternal circulation and not
from foetal synthesis. There is evidence that poly(I:C) can
increase the permeability of barriers [69] and it may
therefore contribute indirectly to an increased movement
of cytokines into the foetus.
Overall, the profile of molecular changes described
here suggests that, after exposure in utero to the viral
mimetic poly(I:C), rat pups exhibit abnormal levels of
several proteins known to be important in cerebral de-
velopment. Even though several of the proteins studied
show no significant change, it is important to realise that
the absence of a change may be as scientifically import-
ant as the presence of a change. Firstly, it is valuable evi-
dence that the schedule of immune activation used in
the study does not produce a non-selective toxicity, with
a generalised loss of cells and proteins. Secondly, when
development of the brain can be understood in terms of
the full gamut of molecular changes of expression it is
likely to be just as important to know which aspects of
neuronal development are unaffected by inflammation as
to know which are. In addition, it is highly likely that for
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between molecules that may be the determining factor in
abnormality, especially if different molecular changes occur
at different rates during the course of development. Here
again therefore it will be essential to know which proteins
change in response to insult and which do not.
Finally, we elected to examine the overall protein ex-
pression in cerebral hemispheres. The apparent absence of
a change may, therefore, mask more localised, significant
changes, which need to be investigated in more detail.
Conclusions
By 21 days of age, following the prenatal exposure of rats
to the viral mimetic poly(I:C), there is clear evidence for
changes in the expression of one of the major proteins
associated with neurotransmitter release (VAMP-1), one
involved in NMDA receptor signaling (GluN1) and one
implicated in early neuronal development (sox-2). In view
of the various roles of NMDA receptors in neuronal de-
velopment, these changes could contribute to an altered
rate of new cell production and differentiation reflected in
the altered sox-2 expression. These changes not only lend
strong support to the concept that activation of the im-
mune system during gestation can lead to abnormal brain
development, but also emphasise the central importance
of NMDA receptors. The results are of particular import-
ance to disorders such as schizophrenia, in which reduced
activation of NMDA receptors appears to be a major
cause or trigger of the behavioural abnormalities, and for
which therapies designed to enhance or facilitate NMDA
receptor function may be of clinical value.
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